Comparative Efficacy of Dronedarone and Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
Jonathan P. Piccini, MD, MHS*,
Vic Hasselblad, PhD,
Eric D. Peterson, MD, MPH,
Jeffrey B. Washam, PharmD,
Robert M. Califf, MD and
David F. Kong, MD
Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina
View larger version (19K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Study Selection Process
Shown here is the study selection process according to the Quality of Reporting of Meta-analyses guidelines. The systematic search yielded 4 trials of dronedarone versus placebo, 4 trials of amiodarone versus placebo, and 1 direct head-to-head comparison of amiodarone and dronedarone.
|
|
View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Treatment Effect Estimates for Amiodarone and Dronedarone
The plots demonstrate odds ratios for (A) recurrent atrial fibrillation, (B) all-cause death, and (C) adverse events requiring drug discontinuation with event rates to the right of each panel. A = amiodarone; D = dronedarone; P = placebo; other abbreviations as in Table 1.
|
|
|
